Download PDF
Zentralbl Gynakol 2002; 124(1): 45-50
DOI: 10.1055/s-2002-20309
Therapie nach Evidence based

© Georg Thieme Verlag Stuttgart · New York

Hormon- und Chemotherapie beim Endometriumkarzinom

Hormonal Therapy and Chemotherapy of Endometrial CancerT. Krauß, H. Huschmand, B. Hinney, V. Viereck, G. Emons
  • Universitätsfrauenklinik Göttingen
Further Information

Publication History

Publication Date:
25 February 2002 (online)

    Permissions and Reprints

Zusammenfassung

Da das Endometriumkarzinom meist in den Frühstadien entdeckt und dann chirurgisch ausreichend therapiert wird, kommen Hormon- und Chemotherapie fast ausschließlich in der palliativen Situation zur Anwendung. Primär sollten dabei die Möglichkeiten der gut verträglichen Hormontherapie mit den zur Verfügung stehenden Gestagenen (Medroxyprogesteronacetat, Megestrolacetat) ausgeschöpft werden. Daneben sind in Einzelfällen auch Tamoxifen oder GnRH-Analoga einsetzbar. Die Ansprechraten sind relativ gering (max. 25 %) und die Remissionsdauern meist kurz. Für die adjuvante Hormontherapie gibt es bisher keine Indikation. - Auch der Nutzen einer adjuvanten Chemotherapie bei Patientinnen mit High-risk-Endometriumkarzinom ist nicht belegt. In Einzelfällen mit hohem Risiko (serös-papillärer Histologie, extrauteriner Ausbreitung) kann postoperativ vor oder nach der Bestrahlung eine adjuvante Chemotherapie erwogen werden. Dabei sind das Alter und die Begleitmorbidität der Patientin zu berücksichtigen. Letztlich bestimmend für die Prognose ist die stadienadaptierte Operation auch bei älteren und adipösen Frauen. - Bisher haben die verschiedenen Chemotherapien beim disseminierten Endometriumkarzinom keinen entscheidenden Durchbruch erzielt. Die empfohlene Standardkombination bleibt bis auf  weiteres Cisplatin/Doxorubicin. Die wichtigste Wirkstoffgruppe sind dabei die Anthracycline. Durch eine Monotherapie mit Doxo- oder Epirubicin lassen sich bei besserer Verträglichkeit befriedigende Behandlungsergebnisse erzielen. Zur Zeit wird in einer multizentrischen Phase-II-Studie die Verträglichkeit und Wirksamkeit von Docetaxel wöchentlich beim rezidivierten oder metastasierten Endometriumkarzinom geprüft.

Summary

Endometrial cancer is usually diagnosed at an early stage where surgery alone is the adequate therapy. Chemotherapy and hormonal treatment are therefore almost exclusively performed in palliative situations. Hormonal treatment with progestogens (medroxyprogesterone acetate and megestrol acetate) should be the therapy of choice primarily as these drugs are very well tolerated. Tamoxifen and GnRH analogs are further options but are seldom used. The response rates to hormonal treatment are relatively low (max. 25 %) with short remissions in most cases. - So far neither hormonal treatment nor cytotoxic chemotherapy has been shown to have substantial benefits in the adjuvant setting. In some selected high risk cases (serous papillary carcinomas, extra uterine manifestation) adjuvant chemotherapy may be an option following surgery, before or after radiotherapy. Age, general condition and morbidity of the patients need to be considered as limiting factors for chemotherapy. Crucial for the prognosis of all endometrial cancer patients however, is the stage adapted surgery. - Cytotoxic chemotherapy has failed to bring a break through in the therapy of advanced endometrial cancer. Cisplatin plus doxorubicin is the standard combination to date, with anthracyclines being the more important component. In a mono-therapy setting, doxorubicin and epirubicin are well tolerated and convenient in their efficacy.  For recurrent and metastatic disease, docetaxel is being evaluated for efficacy and side effects in a multicenter phase II trial.

Schlüsselwörter

Endometriumkarzinom - Hormontherapie - Chemotherapie - Prognose

Key words

Endometrial cancer - Hormonal therapy - Chemotherapy - Prognosis

Literatur

  • 1 Agorastos T, Bontis J, Vakiani A, Vuvilis P, Constantinidis T. Treatment of endometrial hyperplasia with gonadotropin releasing hormone agonists: pathological, clinical, morphometric and DNA-cytometric data.  Gynecol Oncol. 1997;  65 102-114
    CrossrefPubMedGoogle Scholar
  • 2 Ball H G, Blessing J A, Lentz S S, Mutch D G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.  Gynecol Oncol. 1996;  62(2) 278-281
    CrossrefPubMedGoogle Scholar
  • 3 Burke T W, Gershenson D M, Morris M, Stringer C A, Levenback C, Tortolero-Luna G, Baker V V. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.  Gynecol Oncol. 1994;  55(1) 47-50
    CrossrefPubMedGoogle Scholar
  • 4 Chambers  Joseph T, Rutherford T J, Schwartz P E, Carcangiu M L, Chambers S K. A pilot study of topotecan for the treatment of serous endometrial cancer. St. Luke's-Roosevelt Hospital Center, New York, NY; Yale University, New Haven CT, ASCO 2001 Abstract-Nr. 872
    Google Scholar
  • 5 Cohen C J, Rahaman J. Endometrial cancer.  Cancer. 1995;  76 2044-2052
    PubMedGoogle Scholar
  • 6 COSA-NZ-UK Endometrial Cancer Study Groups 1998 . Adjuvant medroxyprogesterone acetate in high risk endometrial cancer.  Int J Gynecol Cancer. 1998;  8 387-391
    CrossrefPubMedGoogle Scholar
  • 7 Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Franssen E, Roche K. A phase II study of leuprolide in advanced/recurrent endometrial cancer.  Gynecol Oncol. 1997;  64 126-129
    CrossrefPubMedGoogle Scholar
  • 8 De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormontherapy accordino to pathological prognostic groups. Long-term results of a randomized multicenter study.  Eur J Cancer. 1993;  29 1133-1140
    PubMedGoogle Scholar
  • 9 De Vriese G, Bonte J. Possible role of goserelin, an LHRH agonist, in the treatment of gynecological cancers.  Eur J Gynaecol Oncol. 1993;  14 187-191
    PubMedGoogle Scholar
  • 10 Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer.  Endocr Relat Cancer. 2000;  7(4) 227-242
    CrossrefPubMedGoogle Scholar
  • 11 Emons G, Heyl W. Hormonal treatment of endometrial cancer.  J Cancer Res Clin Oncol. 2000;  126(11) 619-623
    PubMedGoogle Scholar
  • 12 Emons G, Müller V, Ortmann O, Grossmann G, Trautner U, v Stuckrad B, Schulz K-D, Schally A V. Luteinizing hormone releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines.  Int J Oncology. 1996;  9 1129-1137
    PubMedGoogle Scholar
  • 13 Emons G, Ortmann O, Schulz K-D, Schally A V. Growth-inhibiting actions of analogues of luteinizing hormone releasing hormone on tumor cells.  Trends Endocrinol Metab. 1997;  8 355-362
    PubMedGoogle Scholar
  • 14 Gallagher C J, Oliver R TD, Oram D H, Fowler C G, Blake P R, Mantell B S, Slevin M L, Hope-Stone H F. A new treatment for endometrial cancer with gonadotrophin releasing hormone analogue.  Br J Obstet Gynecol. 1991;  98 1037-1041
    PubMedGoogle Scholar
  • 15 Günthert A R, Pilz S, Kuhn W, Emons G, Meden H. Docetaxel is effective in the treatment of metastatic endometrial cancer.  Anticancer Res. 1999;  19 3459-3461
    PubMedGoogle Scholar
  • 16 Hoskins P, Swenerton K, Pike J, Wong F, Lim P, Aquino-Parsons C, Lee N. Carboplatin/Paclitaxel ± Irradiation for advanced or recurrent endometrial cancer. British Columbia Cancer Agency, Vancouver, BC, Canada, ASCO 2001, Abstract-Nr. 820
    Google Scholar
  • 17 Jeyarajah A R, Gallagher C J, Blake P R, Oram D H, Dowsett M, Fisher C, Oliver R TD. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer.  Gynecol Oncol. 1996;  63 47-52
    CrossrefPubMedGoogle Scholar
  • 18 Kim Y B, Holschneider C H, Gosh K, Nieberg R K, Montz F J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.  Cancer. 1997;  79 320-327
    CrossrefPubMedGoogle Scholar
  • 19 Kurman R J, Kalminski P F, Norris H J. The behavior of endometrial hyperplasia: a long term study of ‘untreated’ hyperplasia in 170 patients.  Cancer. 1985;  6 403-412
    PubMedGoogle Scholar
  • 20 Le T D, Yamada S D, Rutgers J L, DiSaia P J. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.  Gynecol Oncol. 1999;  73 461-463
    CrossrefPubMedGoogle Scholar
  • 21 Lentz S S, Brady M F, Major F J, Reid G C, Soper J T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.  J Clin Oncol. 1996;  14 357-361
    PubMedGoogle Scholar
  • 22 Levenback C, Burke T W, Silva E, Morris M, Gershenson D M, Kavanagh J J, Wharton J T. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).  Gynecol Oncol. 1992;  46 317-321
    CrossrefPubMedGoogle Scholar
  • 23 Lewis G C, Slack N H, Mortel R, Brass I. Adjuvant progestogen therapy in the definitive treatment of endometrial cancer.  Gynecol Oncol. 1974;  2 368-376
    CrossrefPubMedGoogle Scholar
  • 24 Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, Sessa C. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma.  Ann Oncol. 1997;  8 969-972
    CrossrefPubMedGoogle Scholar
  • 25 MacDonald R R, Thorogod J, Mason M K. A randomized trial of progestogens in the primary treatment of endometrial carcinoma.  Br J Obstet Gynecol. 1988;  95 166-174
    PubMedGoogle Scholar
  • 26 Malkasian G D, Decker D G. Adjuvant progesterone therapy for stage I endometrial carcinoma.  Int J Gynecol Obstet. 1978;  16 48-49
    PubMedGoogle Scholar
  • 27 Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Leuprolide in the treatment of endometrial cancer.  Gynecol Oncol. 1997;  66 542
    PubMedGoogle Scholar
  • 28 Martin-Hirsch P L, Lilford R J, Jarvis G J. Adjuvant progestogen  therapy for the treatment of endometrial cancer: a review and meta-analysis of published randomized controlled trials.  Eur J Obstet Gynecol Reprod Biol. 1996;  65 201-207
    CrossrefPubMedGoogle Scholar
  • 29 Moore T D, Phillips P H, Nerenstone S R, Cheson B D. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.  J Clin Oncol. 1991;  9 1071-1088
    PubMedGoogle Scholar
  • 30 Morrow C P, Bundy B N, Homesley H D, Creasman W T, Hornback N B, Kurman R, Thigpen J T. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study.  Gynecol Oncol. 1990;  36 166-171
    CrossrefPubMedGoogle Scholar
  • 31 Murray R ML, Pitt P. Treatment of advanced metastatic breast cancer, carcinoma of the prostate and endometrial cancer with aminoglutethimide. In: Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer.  GA Nagel, RJ Santen (Eds). Huber, Bern 1984; 109-122
    Google Scholar
  • 32 Paulson R J, Saure M V, Lobo P A. Pregnancy after in vitro fertilization in a patient with stage I endometrial carcinoma treated with progestins.  Fertil  Steril. 1990;  54 735-736
    PubMedGoogle Scholar
  • 33 Quinn M A. Hormonal treatment of endometrial cancer.  Hematol Oncol Clin North Am. 1999;  13 163-187
    CrossrefPubMedGoogle Scholar
  • 34 Randall T C, Kurman R J. Progestin treatment of atypical hyperplasia and well differentiated carcinoma of the endometrium in women under age 40.  Obstet Gynecol. 1997;  90 434-440
    CrossrefPubMedGoogle Scholar
  • 35 Resnik E, Taxy J B. Neoadjuvant chemotherapy in uterine papillary serous carcinoma.  Gynecol Oncol. 1996;  62 123-127
    CrossrefPubMedGoogle Scholar
  • 36 Smith M R, Peters W A, Drescher C W. Cisplatin, doxorubicin, hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.  Am J Obstet Gynecol. 1994;  170 1677-1681
    PubMedGoogle Scholar
  • 37 [The Surveillance, Epidemiology, and End Results (SEER)].  Program of the National Cancer Institute (2001), http://seer.cancer.gov
    Google Scholar
  • 38 Thigpen J, Blessing H, Homesley H, Malfetano J, DiSaia P J, Yordan E. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study.  Proc Am Soc Clin Oncol. 1993;  12 261
    PubMedGoogle Scholar
  • 39 Thigpen J T, Blessing J A, DiSaia P J, Yordan E, Carson L F, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.  J Clin Oncol. 1994;  12 1408-1414 
    PubMedGoogle Scholar
  • 40 Thigpen J T, Brady M F, Alvarez R D, Adelson M D, Homesley H D, Manetta A, Soper J T, Given F T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.  J Clin Oncol. 1999;  17 1736-1744
    PubMedGoogle Scholar
  • 41 Urbanski K, Karolewski K, Kojs Z, Klimek M, Dyba T. Adjuvant progestogen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of a one-institutional prospective clinical trial.  Eur J Gynecol Oncol. 1993;  14 98-104
    PubMedGoogle Scholar
  • 42 Verschraegen C F, Matei C, Loyer E, Malpica A, Tornoss C, Kudelka A P, Kavanagh J J. Octreotide induced remission of a refractory small cell carcinoma of the endometrium.  Int J  Gynecol Cancer. 1999;  9 80-85
    PubMedGoogle Scholar
  • 43 Vinker S, Shani A, Open M, Fenig E, Dgani R. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is is appropriate?.  Eur J Obstet Gynecol Reprod Biol. 1999;  83 63-65
    CrossrefPubMedGoogle Scholar
  • 44 Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestogen in early endometrial cancer.  Cancer. 1989;  64 1011-1016
    PubMedGoogle Scholar
  • 45 Zanotti K M, Belinson J L, Kennedy A W, Webster K D, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.  Gynecol Oncol. 1999;  74 272-277
    CrossrefPubMedGoogle Scholar
  • 46 Zuckerman B, Lavie O, Neumann M, Rabinowitz R, Ben-Chetrit A, Voss E, Rosenmann E, Beller V. Endometrial carcinoma stage I grade II. Conservative treatment followed by healthy term pregnancy.  Int J Gynecol Cancer. 1998;  8 172-176
    CrossrefPubMedGoogle Scholar

PD Dr. T. Krauß

Universitäts-Frauenklinik Göttingen

Robert Koch-Str. 40

D-37075 Göttingen

Phone: +49-551/396576

Fax: +49-551/396275

Email: tkrauss@med.uni-goettingen.de

      >